Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience

References

• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011;106:739-49
   PubMed Web of Science ®Google Scholar
• Freedman B, Potpara TS, Lip GYH. Stroke prevention in atrial fibrillation. Lancet 2016;388:806-17
   PubMed Web of Science ®Google Scholar
• Leyden JM, Kleinig TJ, Newbury J, et al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke 2013;44:1226-31
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014;45:2599-605
   PubMed Web of Science ®Google Scholar
• Xian Y, O’Brien EC, Liang L, et al. Association of preceding antithrombotic treatment with acute ischemic stroke severity and in-hospital outcomes among patients with atrial fibrillation. JAMA 2017;317:1057-67
   PubMed Web of Science ®Google Scholar
• Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014;3:CD009893
   PubMed Web of Science ®Google Scholar
• Camm AJ, Pinto FJ, Hankey GJ, et al. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace 2015;17:1007-17
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016;115:31-9
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62
   PubMed Web of Science ®Google Scholar
• Simons LA, Ortiz M, Freedman SB, et al. Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience. Curr Med Res Opin 2016;32:1857-61
   PubMed Web of Science ®Google Scholar
• McHorney CA, Peterson ED, Laliberte F, et al. Comparison of adherence to rivaroxaban versus apixaban among patients with atrial fibrillation. Clin Ther 2016;38:2477-88
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2016;22:1319-29
   PubMedGoogle Scholar
• Gomes T, Mamdani MM, Holbrook AM, et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012;172:1687-9
   PubMed Web of Science ®Google Scholar
• Simons LA, Ortiz M, Germanos P, et al. Persistence on warfarin in patients with atrial fibrillation: experience in Australia 2006–2009. Aust Fam Physic 2013;42:659-61
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol 2016;174:30-42
   PubMed Web of Science ®Google Scholar
• Pandya EY, Bajorek B. Factors affecting patients’ perception on, and adherence to, anticoagulant therapy: anticipating the role of direct oral anticoagulants. Patient 2017;10:163-85
   PubMedGoogle Scholar
• Raparelli V, Proietti M Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2017;117:209-18
   PubMed Web of Science ®Google Scholar
• Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol 2016;72:329-38
   PubMed Web of Science ®Google Scholar
• Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74
   PubMed Web of Science ®Google Scholar
• Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25
   PubMed Web of Science ®Google Scholar
• Johnson ME, Lefèvre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open 2016;6:e011471
   PubMed Web of Science ®Google Scholar
• Lamberts M, Staerk L, Olesen JB, et al. major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. J Am Heart Assoc 2017;6;e004517
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm AJ. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol 2014;37:32-47
   PubMed Web of Science ®Google Scholar
• Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423-34
   PubMed Web of Science ®Google Scholar